Skip to main content
PMC home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1996 Mar 1;24(5):938–942. doi: 10.1093/nar/24.5.938

Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.

Y Ohta 1, H Kijima 1, T Ohkawa 1, M Kashani-Sabet 1, K J Scanlon 1
PMCID: PMC145712  PMID: 8600463

Abstract

In this study, we have compared the efficacy of a tissue-specific promoter (tyrosinase promoter) with a viral promoter to express anti-ras ribozyme RNA in human melanoma cells. The retroviral vector containing the tyrosinase promoter was superior in its ability to suppress the human melanoma phenotype in vitro as characterized by changes in growth, melanin synthesis, morphology and H-ras gene expression. These data support the use of tissue-specific expression of anti-oncogene ribozymes as a rational therapeutic strategy in human cancers.

Full Text

The Full Text of this article is available as a PDF (72.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball N. J., Yohn J. J., Morelli J. G., Norris D. A., Golitz L. E., Hoeffler J. P. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol. 1994 Mar;102(3):285–290. doi: 10.1111/1523-1747.ep12371783. [DOI] [PubMed] [Google Scholar]
  2. Bishop J. M. Molecular themes in oncogenesis. Cell. 1991 Jan 25;64(2):235–248. doi: 10.1016/0092-8674(91)90636-d. [DOI] [PubMed] [Google Scholar]
  3. Castelli C., Sensi M., Lupetti R., Mortarini R., Panceri P., Anichini A., Parmiani G. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. Cancer Res. 1994 Sep 1;54(17):4785–4790. [PubMed] [Google Scholar]
  4. Funato T., Shitara T., Tone T., Jiao L., Kashani-Sabet M., Scanlon K. J. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem Pharmacol. 1994 Oct 7;48(7):1471–1475. doi: 10.1016/0006-2952(94)90572-x. [DOI] [PubMed] [Google Scholar]
  5. Funato T., Yoshida E., Jiao L., Tone T., Kashani-Sabet M., Scanlon K. J. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv Enzyme Regul. 1992;32:195–209. doi: 10.1016/0065-2571(92)90017-t. [DOI] [PubMed] [Google Scholar]
  6. Halaban R., Pomerantz S. H., Marshall S., Lambert D. T., Lerner A. B. Regulation of tyrosinase in human melanocytes grown in culture. J Cell Biol. 1983 Aug;97(2):480–488. doi: 10.1083/jcb.97.2.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hearing V. J., Jiménez M. Analysis of mammalian pigmentation at the molecular level. Pigment Cell Res. 1989 Mar-Apr;2(2):75–85. doi: 10.1111/j.1600-0749.1989.tb00166.x. [DOI] [PubMed] [Google Scholar]
  8. Hug P., Sleight R. G. Liposomes for the transformation of eukaryotic cells. Biochim Biophys Acta. 1991 Jul 26;1097(1):1–17. doi: 10.1016/0925-4439(91)90016-3. [DOI] [PubMed] [Google Scholar]
  9. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther. 1994 Mar;1(1):51–64. [PubMed] [Google Scholar]
  10. Kashani-Sabet M., Funato T., Florenes V. A., Fodstad O., Scanlon K. J. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. 1994 Feb 15;54(4):900–902. [PubMed] [Google Scholar]
  11. Kashani-Sabet M., Funato T., Tone T., Jiao L., Wang W., Yoshida E., Kashfinn B. I., Shitara T., Wu A. M., Moreno J. G. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev. 1992 Spring;2(1):3–15. doi: 10.1089/ard.1992.2.3. [DOI] [PubMed] [Google Scholar]
  12. Kashani-Sabet M., Scanlon K. J. Application of ribozymes to cancer gene therapy. Cancer Gene Ther. 1995 Sep;2(3):213–223. [PubMed] [Google Scholar]
  13. Klüppel M., Beermann F., Ruppert S., Schmid E., Hummler E., Schütz G. The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3777–3781. doi: 10.1073/pnas.88.9.3777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koizumi M., Hayase Y., Iwai S., Kamiya H., Inoue H., Ohtsuka E. Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res. 1989 Sep 12;17(17):7059–7071. doi: 10.1093/nar/17.17.7059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Miller A. D., Rosman G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989 Oct;7(9):980-2, 984-6, 989-90. [PMC free article] [PubMed] [Google Scholar]
  16. Neckers L., Whitesell L., Rosolen A., Geselowitz D. A. Antisense inhibition of oncogene expression. Crit Rev Oncog. 1992;3(1-2):175–231. [PubMed] [Google Scholar]
  17. Ohta Y., Tone T., Shitara T., Funato T., Jiao L., Kashfian B. I., Yoshida E., Horng M., Tsai P., Lauterbach K. H-ras ribozyme-mediated alteration of the human melanoma phenotype. Ann N Y Acad Sci. 1994 May 31;716:242–256. doi: 10.1111/j.1749-6632.1994.tb21716.x. [DOI] [PubMed] [Google Scholar]
  18. Scanlon K. J., Ishida H., Kashani-Sabet M. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11123–11127. doi: 10.1073/pnas.91.23.11123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Scanlon K. J., Jiao L., Funato T., Wang W., Tone T., Rossi J. J., Kashani-Sabet M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10591–10595. doi: 10.1073/pnas.88.23.10591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tone T., Kashani-Sabet M., Funato T., Shitara T., Yoshida E., Kashfian B. I., Horng M., Fodstadt O., Scanlon K. J. Suppression of EJ cells tumorigenicity. In Vivo. 1993 Nov-Dec;7(6A):471–476. [PubMed] [Google Scholar]
  21. Tveit K. M., Fodstad O., Johannessen J. V., Olsnes S. A human melanoma cell line established from xenograft in athymic mice. Br J Cancer. 1980 May;41(5):724–733. doi: 10.1038/bjc.1980.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Vile R. G., Hart I. R. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 1993 Mar 1;53(5):962–967. [PubMed] [Google Scholar]
  23. Vile R. G., Nelson J. A., Castleden S., Chong H., Hart I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994 Dec 1;54(23):6228–6234. [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES